-+ 0.00%
-+ 0.00%
-+ 0.00%

Morgan Stanley Maintains Overweight on Evommune, Raises Price Target to $55

Benzinga·05/11/2026 17:11:39
Listen to the news
Morgan Stanley analyst Judah Frommer maintains Evommune (NYSE:EVMN) with a Overweight and raises the price target from $54 to $55.